Aardvark Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.5%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$3.67next fiscal year
Monitoring Framework
Key Performance Indicators
Cash Runway (Projected Operations) QuarterlyTarget: Into mid-2027
Cash, Cash Equivalents and Short-Term Investments Quarterly91.2M
Dosed Patients in HERO Phase 3 Trial Quarterly68.0
Dosed Patients in OLE Phase 3 Trial Quarterly19.0
Watch Items
- FDA Clinical Hold Resolution on ARD-101 INDTrigger: FDA formal feedback or agreement on protocol modificationsAction: Submit comprehensive safety review, unblinded HERO/OLE data, and proposed dosing adjustments to the FDA.
- Unblinding of HERO and OLE Clinical DataTrigger: Completion of data unblinding and analysis of the 68 randomized and 19 extension patientsAction: Evaluate the overall efficacy and safety profile to determine the therapeutic window and decide on a go/no-go path forward.
- Reversible Cardiac QRS Prolongation Safety ProfileTrigger: Analysis of blood plasma exposure-response relationshipAction: Establish safe therapeutic dosing levels that avoid QRS prolongation observed at above-target doses in healthy volunteers.
Research as of 20 Jun 2026